Cibc World Markets Corp Buys Shares of 4,579 Glaukos Co. (NYSE:GKOS)

Cibc World Markets Corp bought a new position in Glaukos Co. (NYSE:GKOS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 4,579 shares of the medical instruments supplier's stock, valued at approximately $687,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Natixis Advisors LLC increased its position in Glaukos by 1.2% during the 3rd quarter. Natixis Advisors LLC now owns 37,738 shares of the medical instruments supplier's stock worth $4,917,000 after purchasing an additional 441 shares in the last quarter. Thrivent Financial for Lutherans increased its position in shares of Glaukos by 3.2% in the third quarter. Thrivent Financial for Lutherans now owns 43,152 shares of the medical instruments supplier's stock worth $5,622,000 after acquiring an additional 1,339 shares in the last quarter. Pathstone Holdings LLC raised its stake in shares of Glaukos by 6.3% in the 3rd quarter. Pathstone Holdings LLC now owns 22,449 shares of the medical instruments supplier's stock valued at $2,925,000 after acquiring an additional 1,326 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in shares of Glaukos during the 3rd quarter valued at $1,347,000. Finally, Jennison Associates LLC purchased a new stake in Glaukos during the 3rd quarter worth $792,000. Institutional investors and hedge funds own 99.04% of the company's stock.

Insider Activity

In related news, insider Tomas Navratil sold 3,416 shares of Glaukos stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now directly owns 72,437 shares in the company, valued at $10,658,380.18. This trade represents a 4.50 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 6.40% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several research analysts have commented on GKOS shares. Stifel Nicolaus raised their price objective on Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research report on Tuesday, December 31st. Mizuho raised Glaukos from a "neutral" rating to an "outperform" rating and boosted their price target for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. Citigroup upgraded Glaukos from a "neutral" rating to a "buy" rating and upped their price target for the stock from $132.00 to $162.00 in a report on Wednesday, December 11th. Stephens raised shares of Glaukos to a "strong-buy" rating in a research report on Monday, December 2nd. Finally, Needham & Company LLC lifted their price target on shares of Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $163.25.

Glaukos Stock Performance

Shares of GKOS traded down $3.65 during mid-day trading on Wednesday, hitting $103.26. The stock had a trading volume of 479,979 shares, compared to its average volume of 584,967. Glaukos Co. has a fifty-two week low of $87.59 and a fifty-two week high of $163.71. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a market cap of $5.84 billion, a PE ratio of -35.98 and a beta of 0.99. The company's fifty day simple moving average is $133.61 and its two-hundred day simple moving average is $136.29.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. On average, equities analysts expect that Glaukos Co. will post -1.08 earnings per share for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.